September fundraising puts cell therapy and immuno-oncology in the spotlight
PharmaDJ · 10/15/2021
Chinese drugmakers closed 33 financing rounds in September, raising over $1.05 billion. Oncolytic virus therapies developer Virogin Biotech and two CAR-T therapy developers were the biggest fundraisers.
READ MORE

Latest Articles

BeiGene to
Elise Mak · 1 hours ago
In an ongoing dispute surrounding Abraxane (paclitaxel), a drug that BeiGene licensed from BMS' subsidiary Celgene in 2017, the Chinese drugmaker said it intends to contest the termination proposed by its partner "vigorously", and more news from GV20 Oncotherapy, GV20 Oncotherapy, Hengrui Pharma and Anticancer Bioscience.
News
Takeda's Takecab cleared as maintenance therapy of reflux esophagitis in China, and more - Daily news
Elise Mak · 3 days ago
Takeda's Takecab (vonoprazan), an orally bioavailable potassium-competitive acid blocker (P-CAB), was approved for a new indication in China, and more news from Boan Biotech and Eubulus Biotherapeutics.
News
September fundraising puts cell therapy and immuno-oncology in the spotlight
PharmaDJ · 3 days ago
Chinese drugmakers closed 33 financing rounds in September, raising over $1.05 billion. Oncolytic virus therapies developer Virogin Biotech and two CAR-T therapy developers were the biggest fundraisers.
China Deals Tracker
BioNova licenses Sutro Biopharma's CD74-targeted ADC to Greater China in $204M deal, and more - Daily news
Elise Mak · 4 days ago
BioNova Pharmaceuticals gained Sutro Biopharma's STRO-001, a phase I-stage CD74-targeting ADC, to develop and commercialize it in hematologic cancers in Greater China, and more news from Abbisko and Fosun Pharma.
News
Chinese cancer drugmakers win more approvals than ever but their focus too narrow, regulators say
Minhua Chu · 5 days ago
For the first time, Chinese drugmakers have won more approvals for cancer drugs than their foreign peers, but drug development is too concentrated in oncology and certain targets, regulators said at two recent conferences.
Regulatory
Hansoh inks $456.5M deal with OliX to foray into siRNA therapeutics, and more - Daily news
Elise Mak · 5 days ago
Hansoh Pharmaceutical Group made a partnership with South Korea's OliX Pharmaceuticals to discover, develop and commercialize siRNA therapeutics in key targeted indications in Greater China, and more news from Sciwind Biosciences and SciClone.
News
Brii: EUA filing for Merck’s molnupiravir won’t impact plan for BRII-196/BRII-198
Elise Mak · 6 days ago
Brii Biosciences has injected $100 million to prepare for the COVID-19 therapy’s launch and will first eye the U.S., China, Brazil, South Africa, Mexico and Argentina, its vice president and head of infectious diseases David Margolis told PharmaDJ.
Feature
Biocytogen taps TRACON to develop CTLA-4 antibody in North America, and more - Daily news
Elise Mak · 6 days ago
Biocytogen taps TRACON to develop CTLA-4 antibody in North America, and more news from China Immunotech, Janssen, Sanofi and BeiGene.
News
Brii seeks EUA for COVID combo therapy BRII-196/BRII-198, and more - Daily News
Elise Mak · 7 days ago
Brii seeks EUA for COVID combo therapy BRII-196/BRII-198, and more news from BeBetter Med, CStone and Jinfeng Biotech.
News
Chineo raises over $15.5M in extra pre-B round to advance super TIL therapy, and more - Daily news
Elise Mak · 10 days ago
Chineo raised over $15.5M in an extra pre-B round to advance "super TIL" therapy. More news from Ambrx, Junshi Biosciences, Junshi Biosciences and Leads Biolabs.
News
Copyright © 2016-2021 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement